A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton’s tyrosine kinase inhibitors (BTKis) single and its combination therapy
Sign Up to like & getrecommendations! Published in 2024 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2024.2327507
Abstract: ABSTRACT Background Bruton’s tyrosine kinase inhibitors (BTKis) are targeted treatments for B-cell tumors but have significant side effects. This study assesses and contrasts the side effects of BTKis alone and its four combination therapies. Research… read more here.
Keywords: fda adverse; inhibitors btkis; tyrosine kinase; adverse event ... See more keywords
Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
Sign Up to like & getrecommendations! Published in 2023 at "Molecules"
DOI: 10.3390/molecules28052400
Abstract: In the last few decades, there has been a growing interest in Bruton’s tyrosine kinase (BTK) and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) signaling pathway and… read more here.
Keywords: bruton tyrosine; kinase; tyrosine kinase; btk inhibitors ... See more keywords